Skip to main content

View Resource

Published

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial.
Thuluva S. The Lancet Regional Health - Southeast Asia 2025;:https://doi.org/10.1016/j.lansea.2025.100642.
[The new XBB.1.5 RBD subunit vaccine was found to be both safe and robustly immunogenic when administered as a two-dose booster series in individuals aged 5–80 years. The vaccine induced a significant rise in neutralising antibodies against the XBB.1.5 strain as well as cross-protective neutralising antibodies against the JN.1 SARS-CoV-2 strain. These data are in line with studies of other XBB.1.5 monovalent vaccines and support a positive risk-benefit profile.]
Freely available online
Age Groups
Adults
Children
Older People
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Population Health
Staff Groups
Immunisation
Public Health Doctor
Public Health Specialist